Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

UFS hones focus to nurture world-class research - Business Day
2006-02-10

 

Sue Blaine
THE University of the Free State plans to concentrate academic study in five areas to strengthen its status as a research institution, the university said yesterday.

The Bloemfontein-based university will focus on areas it classes as development (economics, health, literacy and other human activities) and social transformation — an analysis of how South African society is changing from a philosophical and political viewpoint.

The other three research areas are new technologies, water resources and security, and food production and security.

“It makes sense to concentrate the university’s human resources, infrastructure, financial resources and intellectual expertise,” said university rector and vice-chancellor Prof Frederick Fourie.

The move introduces a style of research that matches international trends.

Universities in Canada, Britain and Australia are setting up their research departments in this way.

In SA, the universities of Stellenbosch, the Witwatersrand, Cape Town and KwaZulu-Natal have embarked on similar strategies.

Fourie gave the example of his alma mater, the US’s Harvard University, whose Nanoscale Science and Engineering Centre is an example of “clustering” on a larger scale.

The centre is a collaboration with Harvard, the Massachusetts Institute of Technology, the University of California, Santa Barbara, the Museum of Science, Boston, and universities in the Netherlands, Switzerland and Japan.

Fourie said the modern research world was so diverse and complex that no university could cover all bases so it was better to establish areas of expertise that made it different from its peer institutions.

Having scientists and researchers work in teams meant certain issues could be researched and developed in a multidisciplinary manner. “I think it’s the only way in which any university can excel. This will help SA become world class in selected areas,” Fourie said.

It is in chemistry that the cluster model has already had its most visible results, with a slice of the university’s on-campus pharmacological testing company Farmovs, established in the 1980s, sold to the US’s Parexel International.

The company is one of the largest biopharmaceutical outsourcing organisations in the world, providing knowledge-based contract research, medical marketing and consulting services to the global pharmaceutical, biotechnology and medical device industries, according to Biospace, an internet-based company providing resources and information to the life science industry.

President Thabo Mbeki, in his state of the nation address last Friday, committed government to allocating more resources to research, development and innovation, and increasing the pool of young researchers in SA.

He said government would “continue to engage the leadership of our tertiary institutions focused on working with them to meet the nation’s expectations with regard to teaching and research”.

The university used to be home to several A-rated scientists, who are considered by a peer review, conducted by the National Research Foundation, to be world leaders in their fields, but had lost them to other institutions. Fourie hopes to lure them back, and with them postgraduate students and funding for their work.

“At universities where you get a star researcher they tend to attract people and funding; if they leave they take that with them,” he said.

Fourie said R50m would be spent on the project, with some already spent last year and the last disbursements to be made next year.

There is R10m in seed money to gather experts and improve equipment and infrastructure, and R17m has been invested in chemistry equipment and staff.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept